ライフサイエンスコーパス: flu

1 -related visits to emergency departments (ED(flu)).

2 ivo anti-fibrotic properties of fluvastatin (Flu).

3 romaticity indices (HOMA, NICS-XY, ACID, and FLU).

4 arate, context-specific estimates of P(ILI | Flu).

5 cytic choriomeningitis (LCMV) and influenza (Flu).

6 ficantly suppressed by pre-treating HSC with Flu.

7 o (1)O(2) reported in the Arabidopsis mutant flu.

8 imum compared to controls without mycelia or FLU.

9 against future outbreaks of lethal pandemic flu.

10 nizations, including those for pneumonia and flu.

11 class adjuvants being developed for pandemic flu.

12 inated or are exposed to friends who get the flu.

13 owed similar adsorption properties for NA or FLU.

14 ing mild infections like common colds or the flu.

15 tal relevant concentrations of 6 and 42 ng/L FLU.

16 In FLU 002 28/528 (5.3%) outpatients had influenza A(H1N1)p

17 follow-up for those seeking outpatient care (FLU 002) or after 60 days for those hospitalized with in

18 ations, hospitalization or death, whereas in FLU 003 28/170 (16.5%) inpatients enrolled from the gene

19 e hospitalized with influenza complications (FLU 003).

20 In vitro, Flu (1-20 muM) inhibited PA-induced free-radical product

21 t, 34.3%; ear infection, 26.2%; and colds or flu, 19.2%) and for physicals (13.1%).

22 CDAA diet with vehicles, and CDAA diet with Flu (5 mg/kg or 10 mg/kg) (n = 8 each) through gavage fo

23 min (12% and 50%, respectively) compared to FLU (94%).

24 ked" sputum and NTS samples for influenza A (Flu A), respiratory syncytial virus (RSV), coronavirus O

25 sts for influenza, the BD Veritor System for Flu A+B (BD) and the Alere BinaxNOW influenza A&B card (

26 d sputum samples compared to NTS samples for Flu A, RSV, and HMPV (P = 0.0001, P = 0.006, and P = 0.0

27 The Luminex Aries Flu A/B & RSV assay is a fully automated sample-to-answe

28 This study demonstrates that the Aries Flu A/B & RSV assay is a suitable method for rapid and a

29 The clinical performance of the Aries Flu A/B & RSV assay was prospectively evaluated in compa

30 nal clinical sensitivity values of the Aries Flu A/B & RSV assay were 98.1% for influenza A virus, 98

31 nd were all accurately detected by the Aries Flu A/B & RSV assay.

32 luenza A and B real-time PCR assay (Simplexa Flu A/B & RSV Direct; Focus Diagnostics) using respirato

33 To compare Simplexa Flu A/B & RSV PCR with cytospin-immunofluorescence and l

34 igene RV+ and the Focus Diagnostics Simplexa Flu A/B & RSV tests.

35 enza A&B test compared to those of the Xpert flu A/B assay.

36 th Carolina/1/1918, 18HA), the 2009 pandemic flu (A/California/04/2009, 09HA), a 2009 pandemic flu mu

37 ia/04/2009, 09HA_mut), and the 2006 seasonal flu (A/Solomon Islands/3/2006, 06HA).

38 en Ig-2D1 and the HAs from the 1918 pandemic flu (A/South Carolina/1/1918, 18HA), the 2009 pandemic f

39 respiratory viruses, particularly influenza (Flu), a virus responsible for substantial worldwide morb

40 The effects of FLU, a pesticide that is reported to be safer than neoni

41 nfluenza vaccination and correlate with anti-flu Ab responses, indicating a fully functional populati

42 disrupt PA-PB1 subunits interaction and anti-Flu activity with no cytotoxicity.

43 s being particularly suitable to impart anti-Flu activity.

44 We found that flu adjuvanticity correlates with the upregulation of pr

45 ess, suggesting possible therapeutic role of Flu against NASH.

46 In vivo, Flu alleviated steatosis-induced HSC activation and hepa

47 Flu also reduced steatosis and fibrosis scores, alpha-SM

48 of the singlet oxygen ((1)O2)-overproducing flu and chlorina1 (ch1) mutants of Arabidopsis (Arabidop

49 Transcript profile analysis of flu and flu caa39 mutants revealed that Topo VI is neces

50 of 96 discrepant results between the PLEX-ID Flu and ProFLU+/ProFAST+ assays were found upon influenz

51 We demonstrate that Flu and RV, another common respiratory virus, induce gly

52 subtypes (which include both the H1N1 swine flu and the H5N1 bird flu), the relative binding affinit

53 55 nm (for the determination of OXO, NAL and FLU) and 275 nm (for CIP, DAN, ENR and SAR) by means of

54 elative to isogenic control tumor (PSMA- PC3 flu) and background tissue.

55 to heterologous infections like influenza A (Flu) and cytomegalovirus (CMV).

56 apeutic options against the influenza virus (flu) and increasing challenges in drug resistance make t

57 Three CECs (carbamazepine (CBZ), flumequine (FLU), and thiabendazole (TBZ) at 100 mug L(-1)) and two

58 received conditioning with TBI 300 cGy, CY, FLU, and ATG.

59 ce of monitoring PA reassortment in seasonal flu, and confirm the role of the Caspase-1 gene in influ

60 that includes information about vaccination, flu, and face-to-face social networks.

61 The PLEX-ID Flu assay (Abbott Molecular Inc., Des Plaines, IL) incor

62 veloped tests (LDTs) (n = 207) and the Xpert Flu assay (n = 147) using archived nasopharyngeal swabs.

63 ecimen was tested in parallel by the PLEX-ID Flu assay and by the Prodesse ProFLU+ assay (Prodesse In

64 The PLEX-ID Flu assay demonstrated a high level of accuracy for the

65 ult analysis, the sensitivities of the Xpert Flu Assay for prospective NA-W specimens containing the

66 irus subtyping characterization, the PLEX-ID Flu assay had PPAs and NPAs of 98.3% and 97.5% for H1N1-

67 the performance of Cepheid's GeneXpert Xpert Flu assay in a target population of 281 adults presentin

68 l performance characteristics of the PLEX-ID Flu assay in symptomatic patients were determined in thi

69 We conclude that the Cepheid Xpert Flu Assay is an accurate and rapid method that is suitab

70 The reproducibility of the PLEX-ID Flu assay ranged from 98.3 to 100.0%, as determined by t

71 mparing the results of the new Cepheid Xpert Flu Assay to those of culture or real-time PCR with arch

72 ive percent agreements (NPAs) of the PLEX-ID Flu assay were 94.5% and 99.0% for influenza A virus and

73 The sensitivities of the Xpert Flu Assay with archived NP specimens compared to those o

74 Xpert Flu/RSV XC assay compared to the Xpert Flu assay.

75 FLU at higher doses resulted in similar learning impairm

76 bed corticosteroid, fludrocortisone acetate (FLU), at concentrations between 0.006 and 42 mug/L.

77 nce, we could show that physically separated FLU becomes bioavailable to bacteria after transport by

78 cell, it was also as a bacterial reporter of FLU bioavailability in the vicinity of mycelia.

79 , Flu/busulfan (Bu)/alemtuzumab (n = 8), and Flu/Bu/antithymocyte globulin (n = 1).

80 However, a substantial part of the annual flu burden is caused by two cocirculating, antigenically

81 rabine (Flu)/melphalan/alemtuzumab (n = 20), Flu/busulfan (Bu)/alemtuzumab (n = 8), and Flu/Bu/antith

82 such as nalidixic acid (NA) and flumequine (FLU), but also salicylic acid (SA), natural organic matt

83 examined the role of RNAi in host defense to flu by analyzing Argonaute 1 and 3 double-knockout mice

84 thermore, degradation of mycelia-transported FLU by the bacterium Burkholderia sartisoli RP037-mChe w

85 Here, we test protection against avian flu by using H5N1-derived rHA and GLA-SE, a two-part adj

86 demonstrated transport of the PAH fluorene (FLU) by the mycelial oomycete Pythium ultimum that was g

87 Transcript profile analysis of flu and flu caa39 mutants revealed that Topo VI is necessary for

88 ogenic survival when compared with PSMA- PC3 flu cells.

89 The Influenza Clinical Information Network (FLU-CIN) was established to gather detailed clinical and

90 to host cells) sequence available from NCBI flu database, and showed an overall correspondence and l

91 d failed to enhance the adaptive response to flu despite a strong activation of the IFN pathway in mu

92 only a small fraction of those with seasonal flu dies, most often the oldest, youngest, and sickest.

93 The lower FLU doses decreased average olfactory learning by 74% (l

94 Analytically, the SAMBA Flu duplex test detects 95 and 85 copies of viral genome

95 The SAMBA Flu duplex test showed a clinical sensitivity and specif

96 the SAMBA (simple amplification-based assay) Flu duplex test, is a dipstick-based molecular assay dev

97 ified protein derivative, Tetanus toxoid, or flu/EBV/CMV viral mix) in LN, despite strong responses i

98 r', or 'runny nose when not having a cold or flu', either usually or in the last 12 months.

99 ent in the ability of lung cells to tolerate flu-elicited inflammation.

100 d1 and rfd2 had genetic lesions in RIBA1 and FLU encoding the dual-functional protein GTP cyclohydrol

101 The addition of FLU enhanced engraftment 3-fold.

102 B viruses are the primary cause of seasonal flu epidemics.

103 a A virus, influenza B virus causes seasonal flu epidemics.

104 in mice bearing PSMA+ PC3 PIP and PSMA- PC3 flu flank xenografts at a 740-kBq dose and in mice beari

105 in mice bearing PSMA+ PC3 PIP and PSMA- PC3 flu flank xenografts.

106 nude mice bearing PSMA+ PC3 PIP or PSMA- PC3 flu flank xenografts.

107 his organism expresses eGFP in response to a FLU flux to the cell, it was also as a bacterial reporte

108 globulin (ATG) with or without fludarabine (FLU), followed by T-cell-depleted bone marrow or unmanip

109 d glass fibers capturing mycelia-transported FLU guided us to propose a three-step mechanism of passi

110 gh this means to anti-Langerin rAbs elicited Flu HA1-specific Ab and T cell responses in mice.

111 pared with the Prodesse ProFlu+ assay, Xpert Flu had an overall sensitivity of 95.3% and specificity

112 gned to reveal immune strategies against the flu has uncovered an Achilles' heel for influenza replic

113 PSMA+) PC3 PIP and PSMA-negative (PSMA-) PC3 flu human PC cells after (211)At- 6: treatment.

114 PSMA+) PC3 PIP and PSMA-negative (PSMA-) PC3 flu human prostate cancer cells after treatment with (12

115 ate flu vaccine delivery platform to control flu in humans.

116 nny or blocked nose episodes without cold or flu in the first year of life.

117 es to indications about the current state of flu in various places all over the world.

118 ildren aged 6-18 years, the percentage of ED(flu) in IC remained constant (5.1% before vs 5.2% during

119 g fenbendazole (FBZ) and flunixin meglumine (FLU) in swine liver.

120 or >1 h, or runny nose without having a cold/flu) in the last year.

121 xposure of human myeloid DCs to IFN-alpha or Flu increases TLR7 expression, suggesting they may have

122 to the B27/NP383-391 epitope in influenza A (flu)-infected B27/ERAP(-/-) mice.

123 ession seen for the same allele in naive and flu-infected B27/ERAP(+/+) mice.

124 HLA-B27 surface expression in naive and flu-infected B27/ERAP(-/-) mice is also lower than the e

125 The B7-restricted NP418-426 CTL response in flu-infected B7/ERAP(-/-) and B7/ERAP(+/+) mice was also

126 Compared to littermate controls, flu-infected double-knockout mice exhibited increased mo

127 en-negative live cells in the lungs of Color-flu-infected mice.

128 ffective NK cell responses in the context of flu infection and delineate NK cell signaling pathways r

129 Employee absenteeism caused by flu infection costs hundreds of millions of dollars ever

130 th iNOS promoter during in vitro and in vivo flu infection of human lung cells and mouse respiratory

131 s noted in the lungs following intratracheal flu infection of iNOS knockout mice.

132 al transduction molecules showed that during flu infection, STAT1 activation in NK cells was complete

133 velopment of exaggerated lung disease during flu infection, the underlying mechanism, including the r

134 both IFN-gamma and granzyme B in response to flu infection.

135 ivity, and expression of iNOS mRNA following flu infection.

136 or essential for iNOS gene expression during flu infection.

137 vir (Laninamivir Octanoate Hydrate) to treat flu infection.

138 lities of self-reported ILI given influenza (Flu) infection (P(ILI | Flu)), which were obtained from

139 Although seasonal flu infects as much as 20% of the world's population-mor

140 w indicators of aromaticity such as the PDI, FLU, ING, and INB were defined in our group.

141 ting the lower respiratory tract, and that S-FLU is a promising universal influenza vaccine candidate

142 Flu is caused by the influenza virus that, due to mutati

143 how that when given by inhalation to mice, S-FLU is nonpathogenic but generates a vigorous T cell res

144 Influenza A virus (flu) is a respiratory tract pathogen causing high morbid

145 tive-sense RNA virus influenza virus type A (flu) is unclear.

146 rom the United States, we find that seasonal flu leaves a transient wake of heterosubtypic immunity t

147 phyll precursors as observed in fluorescent (flu)-like mutants.

148 ative bacterium that causes human Q fever, a flu-like disease that can progress to chronic, life-thre

149 causes human Q fever, an acute debilitating flu-like illness that can also present as chronic endoca

150 bacterial agent of human Q fever, an acute, flu-like illness that can present as chronic endocarditi

151 nited States can present as undifferentiated flu-like illnesses.

152 people each year are infected worldwide with flu-like pathogens including influenza.

153 (78% with mipomersen, 31% with placebo) and flu-like symptoms (34% with mipomersen, 21% with placebo

154 transient post-DC infusion chills (38%) and flu-like symptoms (84%), dermatitis (64%), hepatitis (13

155 mplications of IFNalpha2b included transient flu-like symptoms (n = 3), corneal epithelial defect (n

156 a zoonotic disease that presents with acute flu-like symptoms and can result in chronic life-threate

157 ine encephalitis virus (VEEV), which elicits flu-like symptoms and encephalitis in humans, with an es

158 ptive transfer to be associated with grade I flu-like symptoms and malaise.

159 grade 1 to 2 pain at the injection site and flu-like symptoms following IDI, some patients receiving

160 rhagic fever characterized by rapid onset of flu-like symptoms often followed by hemorrhagic manifest

161 LD] or symptomatic EBV infection, defined as flu-like symptoms or infectious mononucleosis).

162 Finally, flu-like symptoms were lower in the intervention group.

163 Fever, flu-like symptoms, and fatigue occurred significantly mo

164 ing fever, respiratory distress, nausea, and flu-like symptoms.

165 ), cytomegalovirus viremia (17.8% vs 24.2%), flu-like syndrome (11.6% vs 14.1%), polyoma (BK) viremia

166 In the 3HP arm, 87 (63%) had flu-like syndrome and 23 (17%) had cutaneous reactions;

167 ons, but there have been reports of possible flu-like syndrome.

168 SDR were more common with 3HP, and mostly flu-like.

169 nuclear gene activation after mutagenizing a flu line expressing the luciferase reporter gene under t

170 ntation because it was not detected when the Flu-MA(58-66) Ag was directly loaded on already matured

171 A significant reduction in flu-mediated apoptosis was noted in KLF6-silenced cells,

172 underwent transplantation with RIC by using Flu/Melph and for PIDs by using bone marrow (n = 93) or

173 en with PIDs undergoing transplantation with Flu/Melph RIC from a matched donor source.

174 Ds using RIC with fludarabine and melphalan (Flu/Melph) and to study the effect of donor type and ste

175 ity conditioning (RIC) included fludarabine (Flu)/melphalan/alemtuzumab (n = 20), Flu/busulfan (Bu)/a

176 would allow for greater insight into FBZ and FLU metabolism.

177 A/California/04/2009, 09HA), a 2009 pandemic flu mutant (A/California/04/2009, 09HA_mut), and the 200

178 astid proteins EXECUTER (EX1) and EX2 in the flu mutant abrogates these responses, indicating that di

179 glet oxygen ((1)O(2)) in chloroplasts of the flu mutant of Arabidopsis, reprogramming of nuclear gene

180 ere correlated with the transcriptome of the flu mutant.

181 1 h induction of (1)O2 using the conditional flu mutant.

182 itored first in the conditional fluorescent (flu) mutant of Arabidopsis thaliana that accumulates (1)

183 e safely and effectively combined with IV Bu/Flu myeloablative conditioning and confirms PTCy's effic

184 intravenous busulfan and fludarabine (IV Bu/Flu) myeloablative conditioning as well as graft-versus-

185 Here, we combined Flu Near You data with additional sources (Hong Kong hou

186 fluenza attack rate for the early vaccinated Flu Near You members (vaccination reported by week 45) a

187 We tested the effects of FLU on Apis cerana olfactory learning in larvae (lower d

188 randomly placed into groups: no drug (UNT), FLU or FBZ administered.

189 lolo[3,2-b:4,5-b']dithiophene-2,6-diyl]bis[6-flu oro-4-(5'-hexyl-[2,2'-bithiophene]-5-yl)benzo[c][1,2

190 provide near real-time regional estimates of flu outbreaks in the United States.

191 During the Mexican flu pandemic, a targeted DNA vaccine (HA from A/Californ

192 have been brought to light by the 2009 swine flu pandemic, highly pathogenic avian influenza infectio

193 a viruses and in view of a highly pathogenic flu pandemic, it is important to develop new anti-influe

194 The "Swine flu" pandemic of 2009 caused world-wide infections and d

195 dase type 1 (commonly known as H1N1 or swine flu) pandemic have renewed interest in the role of coinf

196 l-time RT-PCR detection panel (rRT-PCR swine flu panel).

197 In particular, the use for flu patients should be paid careful attention because of

198 vaccination campaigns) and when they get the flu (personalized flu warnings) could have a large impac

199 The flu polymerase acidic (PA), polymerase basic 1 (PB1), an

200 spective, we briefly discuss the validity of flu polymerase as a drug target and its inhibition throu

201 ene expressions in HSC-T6 were suppressed in Flu-pretreated cells compared to those without pretreatm

202 stellate cell line, HSC-T6, with or without Flu-pretreatment for 2 h.

203 g for use of influenza antivirals to prevent flu-related complications are discussed.

204 ese data indicate that optimal resistance to flu requires Argonaute 1 and/or 3.

205 sses relevant to drug metabolism for FBZ and FLU, respectively.

206 Schools that had a Flu Response Team (FRT) as a part of school emergency pr

207 tein 1 (PA-PB1) subunits of influenza virus (Flu) RNA-dependent RNA polymerase, this paper is devoted

208 luenza detection was improved with the Xpert Flu/RSV XC assay compared to the Xpert Flu assay.

209 The Xpert Flu/RSV XC assay was compared to laboratory-developed te

210 = 0.40) led to similar sorbed amounts of NA, FLU, SA, silicates or HA as compared to the stoichiometr

211 ly associated with patient volume during non-flu season (p<0.0001), but only the sales of cough and c

212 and precipitation as driving forces of this flu season and nearly unanimously identified a single ro

213 emic is not predicted well after the peak of flu season has passed.

214 samples of H3N2 influenza during the 2014-15 flu season in the U.S.

215 s the most tropical climate during a typical flu season in the U.S.

216 p<0.0001) categories were significant during flu season with a lag of two and one days, respectively.

217 During peak 2009 H1N1 flu season, children with asthma were infected almost tw

218 e results show that prior to the peak of the flu season, our forecasting method produced 50% and 95%

219 ed in the Northern Hemisphere just after the flu season, suggesting that pandemic timing may be predi

220 e illness rates in the US during the 2012-13 flu season.

221 at did not contain an asthmatic child during flu season.

222 uptake were high, uptake of pneumococcal and flu seasonal vaccinations were low, including among the

223 dictions of the 2014-2015 and 2015-2016 U.S. flu seasons are often more accurate than the same predic

224 13-2014 (retrospective) and 2014-2015 (live) flu seasons for each of the four weekly time horizons.

225 redictive performance using five consecutive flu seasons spanning from 2008 to 2013 and qualitatively

226 H3N2) and 2013-2014 (pandemic H1N1; H1N1pdm) flu seasons.

227 In flu seedlings, (1)O(2)-mediated cell death signaling ope

228 RP-HPLC-DAD-FLU separation enabled us to identify 20 derivatives, in

229 d immune epitope recognition properties, the Flu-SFVT approach allows the rapid identification of the

230 e in the percentage who reported receiving a flu shot (DID, 1.9; 95% CI, -1.93 to 4.93).

231 ch of gene chip analysis, we discovered that Flu significantly affects metabolism in primary human pD

232 ctions, and development of isotype-switched, flu-specific antibody responses.

233 t with no detectable HAI-antibodies but high flu-specific IgG-antibody titers mounted rapid functiona

234 lglycol chitosan produced the most effective flu-specific immune response.

235 ute EBV infection, both preexisting CMV- and Flu-specific memory CD8(+) T cells showed signs of bysta

236 juvant generated significant improvements in flu-specific responses compared with unmodified liposome

237 -cell subsets because a larger proportion of flu-specific T cells has a regulatory cell phenotype in

238 Importantly, the numbers of CMV- and Flu-specific T cells were comparable before and after ac

239 including pandemic 2009 H1N1 and avian H5N1 flu strains, and shows an efficacy profile in a mouse in

240 mic 2009 H1N1 and the highly pathogenic H5N1 flu strains.

241 ct dynamic human response networks for three flu strains: H1N1, H5N1 and H3N2.

242 Using a stochastic model fit to seasonal flu surveillance data from the United States, we find th

243 mework, initially proposed and validated for flu surveillance, to produce near real-time estimates of

244 results support the notion that the enhanced flu susceptibility of double-knockout mice arises from a

245 rologous SwIV H1N1 challenged pigs, clinical flu symptoms were absent, while the control pigs had fev

246 usion in adults undergoing UCBT following Cy/Flu/TBI200 regimen.

247 (TBI), cyclophosphamide, and fludarabine (Cy/Flu/TBI200).

248 de both the H1N1 swine flu and the H5N1 bird flu), the relative binding affinities change only slight

249 Although Flu-TM and TIM express classical phenotypic memory marke

250 memory markers and are polyfunctional, only Flu-TM protects against a lethal viral challenge.

251 -specificity: protective (Influenza-induced, Flu-TM) and non-protective (peptide-induced, TIM) spleen

252 s licensed for treatment of influenza virus (Flu), together with the continuous emergence of viral va

253 ese individual steps to the overall mycelial FLU transport rate.

254 decreased in HSC-T6 cultured with CM from PA-Flu-treated PRHs compared to those cultured with CM from

255 Google Flu Trends (GFT) has generated significant hope that "bi

256 Google Flu Trends (GFT) is a novel Internet-based influenza sur

257 epidemic prediction web tools such as Google Flu Trends (GFT) to assist in risk communication and res

258 e in online search engine data (e.g., Google Flu Trends (GFT)) has received a considerable amount of

259 ed on internet search query data like Google Flu Trends (GFT), are being used as surrogates for clini

260 peak ILI activity 17% more often than Google Flu Trends data and was often more accurate in its measu

261 We show further that Google Flu Trends data, when incorporated into a network as a v

262 d peak height, with and without using Google Flu Trends data.

263 Google Flu Trends embodies the first public platform for transf

264 dels, including the latest version of Google Flu Trends, even though it uses only low-quality search

265 including the recent rise and fall of Google Flu Trends.

266 ium-substituted stannene [Cp*(IXy)(H)2 RuSn(=Flu)Trip] (5) and stanna-imine [Cp*(IXy)(H)2 RuSn(kappa(

267 duced the highest PSMA+ PC3 PIP to PSMA- PC3 flu tumor ratios and demonstrated the lowest retention i

268 SMA-positive PC-3 PIP and PSMA-negative PC-3 flu tumor-bearing mice revealed that (86)Y- 4-6: had hig

269 times volume of less than 15 d for PSMA- PC3 flu tumors and all other treatment groups (P = 0.002 by

270 icity of the seasonal unadjuvanted 2012-2013 flu vaccination suggests that evaluating immunogenicity

271 logical (influenza) and the other is social (flu vaccination).

272 hose >/=65 years and 36.3% of diabetics) had flu vaccination, and 4.4% had pneumococcal vaccination.

273 glutinin antibodies and seasonal inactivated flu vaccine (TIV) can elicit broadly protective antihema

274 ty of a pig model for intranasal particulate flu vaccine delivery platform to control flu in humans.

275 The US Flu Vaccine Effectiveness Network enrolled subjects aged

276 al antibody-based treatments and a universal flu vaccine for all influenza A and B viruses.

277 with a higher dose of a heterologous H5N1 S-FLU vaccine induced weaker BAL and stronger tracheobronc

278 Efforts are underway to develop a universal flu vaccine that would stimulate both the humoral and ce

279 at within 24 h of receiving adjuvanted swine flu vaccine, healthy individuals made expansive, complex

280 Current flu vaccines have failed to provide cross-protection aga

281 Flu vaccines must be reformulated annually, because thes

282 Flu vaccines stimulate B cells in the blood to produce a

283 essitates the almost annual reformulation of flu vaccines, which may offer little protection if the m

284 earliest marker of B-cell response to a new flu virus infection, such as H7N9 in humans.

285 ytokine production in response to influenza (flu) virus.

286 Collectively, Color-flu viruses are powerful tools to analyse virus infectio

287 rol and contain H5N1 influenza viruses, bird flu viruses continue to spread and evolve.

288 istance in most of the currently circulating flu viruses.

289 immunity that impedes the emergence of novel flu viruses.

290 escent proteins of different colours ('Color-flu' viruses) to facilitate the study of viral infection

291 After schools reopened, ARI rates and ED(flu) visits decreased in both communities.

292 The relative increase of total ED(flu) visits in the IC was 27% lower (2.8% before to 4.4%

293 ur study documents a reduction in ARI and ED(flu) visits in the intervention community.

294 both communities, self-reported ARIs and ED(flu) visits increased from before to during the school c

295 gns) and when they get the flu (personalized flu warnings) could have a large impact on reducing the

296 (OXO), nalidixic acid (NAL) and flumequine (FLU) were separated on a Perfectsil ODS-2 120 (250 mm x

297 tinin signal sequence has been suppressed (S-FLU), when administered to pigs by aerosol can induce CD

298 ILI given influenza (Flu) infection (P(ILI | Flu)), which were obtained from separate data (extracted

299 a relatively new pesticide, flupyradifurone (FLU), which has been developed, in part, because it appe

300 y accident) and spread as widely as seasonal flu with anywhere near the current confirmed H5N1 human